Table 1.

Percentage of patients achieving treatment targets

	IDegLira (%)	Insulin glargine U100 (%)	P value
Full DUAL V trial population (IDegLira n = 278, insulin glargine U100 n = 279)
HbA1c ≤6.5%	55.4	30.8	<0.0001
HbA1c ≤6.5% without confirmed hypoglycemia	41.4	19.0	<0.0001
HbA1c ≤6.5% without weight gain	41.7	12.5	<0.0001
HbA1c ≤6.5% without confirmed hypoglycemia and weight gain	31.7	7.5	<0.0001
HbA1c <7.0%	71.6	47.0	<0.0001
HbA1c <7.0% without confirmed hypoglycemia	54.3	29.4	<0.0001
HbA1c <7.0% without weight gain	50.0	19.7	<0.0001
HbA1c <7.0% without confirmed hypoglycemia and weight gain	38.8	12.2	<0.0001
Patients with HbA1c >8.0% at baselineb (IDegLira n = 168, insulin glargine U100 n = 155)
HbA1c ≤6.5%	48.8	20.0	<0.0001
HbA1c ≤6.5% without confirmed hypoglycemia	37.5	12.3	<0.0001
HbA1c ≤6.5% without weight gain	35.7	5.8	<0.0001
HbA1c ≤6.5% without confirmed hypoglycemia and weight gain	27.4	3.2	<0.0001
HbA1c <7.0%	64.3	34.2	<0.0001
HbA1c <7.0% without confirmed hypoglycemia	50.6	20.0	<0.0001
HbA1c <7.0% without weight gain	44.0	11.0	<0.0001
HbA1c <7.0% without confirmed hypoglycemia and weight gain	35.1	6.5	<0.0001
Patients with HbA1c >9.0% at baselineb (IDegLira n = 71, insulin glargine U100 n = 52)
HbA1c ≤6.5%	38.0	13.5	0.0052
HbA1c ≤6.5% without confirmed hypoglycemia	26.8	5.8	0.0087
HbA1c ≤6.5% without weight gain	25.4	0.0	Not defineda
HbA1c ≤6.5% without confirmed hypoglycemia and weight gain	18.3	0.0	Not defineda
HbA1c <7.0%	56.3	23.1	0.0006
HbA1c <7.0% without confirmed hypoglycemia	42.3	11.5	0.0013
HbA1c <7.0% without weight gain	33.8	1.9	0.0026
HbA1c <7.0% without confirmed hypoglycemia and weight gain	26.8	1.9	0.0077

Statistical significance was assessed at the 95% confidence level

HbA1c glycated hemoglobin

^aNo patients in the insulin glargine U100 arm achieved the treatment target and therefore a p value could not be defined

^bPost hoc analysis